BARK receives NYSE non-compliance notice over minimum stock price

BARK, Inc. (NYSE:BARK) has received a NYSE notice for non-compliance, as its stock traded below $1.00 for 30 days, initiating a six-month cure period during which the company may pursue a reverse stock split. This development coincides with the company reporting mixed Q4 2025 results, achieving its first positive adjusted EBITDA for both the quarter and full year and a record gross margin of 63.6%, yet missing revenue expectations at $115.4 million. Analysts have subsequently lowered price targets, reflecting cautious sentiment given the revenue shortfall and the company's decision to withhold full-year FY26 guidance amidst ongoing operational challenges.

Analysis

BARK, Inc. (NYSE:BARK) faces significant regulatory pressure after receiving a NYSE non-compliance notice for its stock trading below the $1.00 minimum for over 30 days. While the company has a six-month cure period and is considering a reverse stock split to regain compliance, this event overshadows its recent operational milestones. The firm reported its first-ever positive full-year adjusted EBITDA in fiscal 2025 and achieved a record quarterly gross margin of 63.6%, signaling improving profitability. However, this progress is contrasted by a material top-line miss, with Q4 revenue of $115.4 million falling short of the $126.78 million forecast. Compounding investor uncertainty, BARK has withheld full-year FY26 guidance due to ongoing challenges, including tariff impacts, and projects only breakeven adjusted EBITDA for Q1. This mixed performance has led analysts at Jefferies and Canaccord Genuity to lower their price targets to $3.00 and $2.00, respectively, reflecting tempered expectations despite a maintained Buy rating from Jefferies.

Key Decisions for Investors

• Investors should closely monitor BARK's ability to regain compliance with the NYSE's $1.00 minimum share price, as failure to do so could lead to delisting and a potential reverse stock split may carry its own risks.
• The core investment thesis hinges on weighing the company's demonstrated operational efficiency, seen in its record gross margins and positive adjusted EBITDA, against persistent revenue weakness and a lack of forward guidance.
• Upcoming earnings reports will be critical, specifically to see if the company achieves its breakeven adjusted EBITDA target for Q1 and provides any color on its strategy to reignite top-line growth.
• Note the divergence in analyst ratings; while price targets have been reduced across the board, the maintenance of a Buy rating by Jefferies suggests some underlying value may be perceived, warranting a closer look at the risk/reward profile for longer-term holders.